Reuters logo
BRIEF-Abbvie announces positive phase 2B data on investigational medicine Elagolix
April 7, 2017 / 12:33 PM / 8 months ago

BRIEF-Abbvie announces positive phase 2B data on investigational medicine Elagolix

April 7 (Reuters) - Abbvie Inc

* Abbvie announces positive phase 2B data demonstrating investigational medicine Elagolix significantly reduced heavy menstrual bleeding in women with uterine fibroids

* Abbvie Inc says phase 3 trials for management of uterine fibroids are ongoing

* Abbvie Inc says study met primary efficacy endpoint

* Abbvie says data demonstrated elagolix, with & without add-back therapy, met primary efficacy endpoint of reduced heavy menstrual bleeding versus placebo Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below